← Back to Search

NMDA Receptor Antagonist

Low-Dose Ketamine (LDK) Treatment Group for Endometriosis

Phase 1
Recruiting
Led By Kathy Huang, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Scheduled to undergo robotic endometriosis removal surgery
Adults, aged 18 to 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative day (pod) 83
Awards & highlights

Study Summary

This trial will study whether a low dose of ketamine can help relieve postoperative pain and recovery in women with chronic pelvic pain who are undergoing robotic removal of endometriosis.

Who is the study for?
This trial is for adult women aged 18-65 with chronic pelvic pain who are scheduled for robotic endometriosis removal surgery. Participants should be medically stable and willing to follow the study procedures throughout its duration.Check my eligibility
What is being tested?
The UPKEEP Study tests if a low dose of ketamine (0.6 mg/kg) can better manage postoperative pain compared to a saline placebo in female patients after robotic endometriosis surgery. It's randomized and single-blinded, meaning participants won't know which treatment they receive.See study design
What are the potential side effects?
Ketamine may cause side effects such as feelings of disconnection from reality, changes in perception, nausea, dizziness, mood swings, or blurred vision. The severity varies among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for a robotic surgery to remove endometriosis.
Select...
I am between 18 and 65 years old.
Select...
I am willing and able to follow the study rules and attend all appointments.
Select...
I have had moderate to severe pelvic pain for more than 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative day (pod) 83
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-operative day (pod) 83 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pelvic Pain Score on Visual Analogue Scale (VAS)
Secondary outcome measures
Change in Opioid Use
Score on Endometriosis Health Profile-30 (EHP-30) Questionnaire
Score on General Anxiety Disorder-7 Screener (GAD-7)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Low-Dose Ketamine (LDK) Treatment GroupExperimental Treatment1 Intervention
Group II: Control GroupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,731 Total Patients Enrolled
Kathy Huang, MDPrincipal InvestigatorNYU Langone Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
NYU Langone Health
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study
2022. "The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05229653.
All > Endometriosis
~7 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top